STAAR Surgical Reports Q1 2025 Financial Results

Staar Surgical ( (STAA) ) has issued an announcement.

On May 7, 2025, STAAR Surgical reported its financial results for the first quarter ending March 28, 2025, revealing a 45% year-over-year decline in net sales to $42.6 million, primarily due to reduced channel inventory in China. Despite this, sales outside China grew by 9%, and the company implemented cost controls and restructuring to align expenses with sales, aiming to resume growth in revenue and Adjusted EBITDA in the second half of the year. The company is also mitigating tariff impacts through consignment agreements in China and expanding manufacturing capabilities in Switzerland. Regulatory approvals in Taiwan and Brazil for its EVO/EVO+ ICLs further strengthen its market position, although the company withdrew its previous financial outlook due to global economic uncertainties and evolving tariff policies.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

Staar Surgical is facing significant challenges, particularly in China, impacting overall financial performance. While there is growth potential outside China, the current financial metrics and technical indicators point to caution. The valuation remains a concern due to negative earnings. Leadership changes could provide strategic direction, but the impact remains to be seen.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical Company, a leader in the field of phakic intraocular lenses (IOLs), specializes in vision correction with its EVO family of Implantable Collamer Lenses (EVO ICL). The company focuses on addressing the growing incidence of myopia globally, leveraging its proprietary Collamer material to provide long-term vision correction solutions.

Average Trading Volume: 1,183,794

Technical Sentiment Signal: Sell

Current Market Cap: $923.2M

See more insights into STAA stock on TipRanks’ Stock Analysis page.